Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Fig. 2

Pain freedom occurred at similar time points in patients using versus not using preventive medications. Patients using (2a) and not using (2b) migraine preventive medications treated a migraine attack with lasmiditan (LTN) 50 mg, 100 mg, or 200 mg of or placebo (PBO). They then rated their pain at 0.5, 1, 1.5, and 2 h postdose. The percentages of patients reporting no pain at each time point are shown in the graph. *p < 0.05 compared to PBO, **p < 0.001 compared with PBO

Back to article page
\